

1. Arvanitakis Z, Schneider JA, Wilson RS, et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. *Neurology* 2008;70:1795–1802.
2. Kivipelto M, Solomon A. Cholesterol as a risk factor for Alzheimer's disease—epidemiological evidence. *Acta Neurol Scand Suppl* 2006;185:50–57.
3. Kivipelto M, Helkala EL, Laakso MP, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. *Ann Intern Med* 2002;137:149–155.
4. Notkola IL, Sulkava R, Pekkanen J, et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. *Neuroepidemiology* 1998;17:14–20.
5. Pappolla MA, Bryant-Thomas TK, Herbert D, et al. Mild Hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. *Neurology* 2003;61:199–205.
6. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. *BMJ* 2001;322:1447–1451.
7. Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. *Arch Neurol* 2002;59:223–227.
8. Li G, Higdon R, Kukull WA, et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. *Neurology* 2004;63:1624–1628.

CORRECTION

Gray matter involvement in multiple sclerosis

In the review article “Gray matter involvement in multiple sclerosis” by I. Pirko et al. (*Neurology*[®] 2007;68:634–642),¹ the authors failed to realize that one panel of a six-panel figure (figure 1, panel D) was published earlier, as part of a paper by Kutzelnigg et al.² (figure 1, panel G). The panel in question represents a brain hemispheric section from a Mayo Clinic patient; the presented schematics were created by Dr. Hans Lassmann's laboratory in Vienna, Austria. Dr. Lucchinetti is the second author of both publications. The authors state they carefully tried to select previously unpublished images for the review paper in *Neurology*¹ and did not realize the overlap between these two panels. The figure legend for figure 1, panel D, should refer to the paper by Kutzelnigg et al.² (reference 5 in the review paper¹). The remaining five panels of figure 1 represent previously unpublished material. The authors apologize for any inconvenience this unintentional oversight may have caused.

1. Pirko I, Lucchinetti CF, Sriram S, Bakshi R. Gray matter involvement in multiple sclerosis. *Neurology* 2007;68:634–642.
2. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. *Brain* 2005;128(Pt 11):2705–2712.

Neurology[®]

CORRECTION

Neurology 2008;71;2021
DOI 10.1212/01.wnl.0000342451.71287.a8

This information is current as of December 8, 2008

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/71/24/2021.full
References	This article cites 2 articles, 1 of which you can access for free at: http://n.neurology.org/content/71/24/2021.full#ref-list-1
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright . All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

